Issue

Vol. 12 (2020)

Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy

https://doi.org/10.1007/s40820-020-00428-y
Wenquan Ou
College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
Kang Sik Nam
School of Mechanical Engineering, Yonsei University, Seoul 03722, Republic of Korea
Dae Hoon Park
School of Mechanical Engineering, Yonsei University, Seoul 03722, Republic of Korea
Jungho Hwang
School of Mechanical Engineering, Yonsei University, Seoul 03722, Republic of Korea
Sae Kwang Ku
College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Republic of Korea
Chul Soon Yong
College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
Jong Oh Kim
College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
Jeong Hoon Byeon
School of Mechanical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea

Corresponding Author: Jeong Hoon Byeon

postjb@yu.ac.kr

Nano-Micro Letters, Vol. 12 (2020), Article Number: 90

Abstract

Because of enhanced efficacy and lower side effects, cancer immunotherapies have recently been extensively investigated in clinical trials to overcome the limitations of conventional cancer monotherapies. Although engineering attempts have been made to build nanosystems even including stimulus nanomaterials for the efficient delivery of antigens, adjuvants, or anticancer drugs to improve immunogenic cancer cell death, this requires huge R&D efforts and investment for clinically relevant findings to be approved for translation of the nanosystems. To this end, in this study, an air–liquid two-phase electrospray was developed for stable bubble pressing under a balance between mechanical and electrical parameters of the spray to continuously produce biomimetic nanosystems consisting of only clinically relevant compounds [paclitaxel-loaded fake blood cell Eudragit particle (Eu-FBCP/PTX)] to provide a conceptual leap for the timely development of translatable chemo-immunotherapeutic nanosystems. This was pursued as the efficacy of systems for delivering anticancer agents that has been mainly influenced by nanosystem shape because of its relevance to transporting behavior to organs, blood circulation, and cell–membrane interactions. The resulting Eu-FBCP/PTX nanosystems exhibiting phagocytic and micropinocytic uptake behaviors can confer better efficacy in chemo-immunotherapeutics in the absence and presence of anti-PD-L1 antibodies than similar sized PTX-loaded spherical Eu particles (Eu-s/PTX).


Article Highlights:


1 A two-phase coaxial electrospray was designed to produce paclitaxel-loaded fake blood cell Eudragit particles (Eu-FBCP/PTX).
2 The chemo-immunotherapeutic efficacy was further enhanced after combining with anti-programmed death-ligand 1 antibodies (Eu-FBCP/PTX + aPL).

Keywords

Cancer immunotherapies Air–liquid two-phase electrospray Paclitaxel-loaded fake blood cell Eudragit particle Translatable chemo-immunotherapeutic nanosystems Anti-PD-L1 antibodies
Ou, Wenquan, Kang Sik Nam, Dae Hoon Park, Jungho Hwang, Sae Kwang Ku, Chul Soon Yong, Jong Oh Kim, and Jeong Hoon Byeon. 2020. “Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy”. Nano-Micro Letters 12 (April):90. https://doi.org/10.1007/s40820-020-00428-y.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. R.H. Fang, A.V. Kroll, L. Zhang, Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy. Small 11, 5483–5496 (2015). https://doi.org/10.1002/smll.201501284
  2. F. Fontana, P. Figueiredo, T. Bauleth-Ramos, A. Correia, H.A. Santos, Immunostimulation and immunosuppression: nanotechnology on the brink. Small Methods 2, 1700347 (2018). https://doi.org/10.1002/smtd.201700347
  3. T. Mishchenko, E. Mitroshina, I. Balalaeva, O. Krysko, M. Vedunova, D.V. Krysko, An emerging role for nanomaterials in increasing immunogenicity of cancer cell death. BBA Rev. Cancer 1871, 99–108 (2019). https://doi.org/10.1016/j.bbcan.2018.11.004
  4. C.-T. Cheng, G. Castro, C.-H. Liu, P. Lau, Advanced nanotechnology: an arsenal to enhance immunotherapy in fighting cancer. Clin. Chim. Acta 292, 12–19 (2019). https://doi.org/10.1016/j.cca.2019.01.027
  5. X. Hu, T. Wu, Y. Bao, Z. Zhang, Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. J. Control. Release 256, 26–45 (2017). https://doi.org/10.1016/j.jconrel.2017.04.026
  6. Z. Gu, Q. Wang, Y. Shi, Y. Huang, J. Zhang, X. Zhang, G. Lin, Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. J. Control. Release 286, 369–380 (2018). https://doi.org/10.1016/j.jconrel.2018.08.011
  7. S.D. Jo, G.-H. Nam, G. Kwak, Y. Yang, I.C. Kwon, Harnessing designed nanoparticles: current strategies and future perspectives in cancer immunotherapy. Nano Today 17, 23–37 (2017). https://doi.org/10.1016/j.nantod.2017.10.008
  8. L. Luo, R. Shu, A. Wu, Nanomaterial-based cancer immunotherapy. J. Mater. Chem. B 5, 5517–5531 (2017). https://doi.org/10.1039/C7TB01137G
  9. W. Ou, J.H. Byeon, R.K. Thapa, S.K. Ku, C.S. Yong, J.O. Kim, Plug-and-play nanorization of coarse black phosphorus for targeted chemo-photoimmunotherapy of colorectal cancer. ACS Nano 12, 10061–10074 (2018). https://doi.org/10.1021/acsnano.8b04658
  10. Z. Wang, W. Liu, J. Shi, N. Chen, C. Fan, Nanoscale delivery systems for cancer immunotherapy. Mater. Horiz. 5, 344–362 (2018). https://doi.org/10.1039/C7MH00991G
  11. Z. Chen, Z. Wang, Z. Gu, Bioinspired and biomimetic nanomedicines. Acc. Chem. Res. 52, 1255–1264 (2019). https://doi.org/10.1021/acs.accounts.9b00079
  12. Z. Wang, B. Guo, E. Middha, Z. Huang, Q. Hu, Z. Fu, B. Liu, Microfluidics-prepared uniform conjugated polymer nanoparticles for photo-triggered immune microenvironment modulation and cancer therapy. ACS Appl. Mater. Interfaces 11, 11167–11176 (2019). https://doi.org/10.1021/acsami.8b22579
  13. R. Mahjub, S. Jatana, S.E. Lee, Z. Qin, G. Pauli, M. Soleimani, S. Madadi, S.-D. Li, Recent advances in applying nanotechnologies for cancer immunotherapy. J. Control. Release 288, 239–263 (2018). https://doi.org/10.1016/j.jconrel.2018.09.010
  14. Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng, Z. Liu, Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 7, 13193 (2016). https://doi.org/10.1038/ncomms13193
  15. Q. Chen, L. Xu, J. Chen, Z. Yang, C. Liang, Y. Yang, Z. Liu, Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy. Biomaterials 148, 69–80 (2017). https://doi.org/10.1016/j.biomaterials.2017.09.021
  16. Y. Zhang, L. Wu, Z. Li, W. Zhang, F. Luo, Y. Chu, G. Chen, Glycocalyx-mimicking nanoparticles improve anti-PD-L1 cancer immunotherapy through reversion of tumor-associated macrophages. Biomacromolecules 19, 2098–2108 (2018). https://doi.org/10.1021/acs.biomac.8b00305
  17. S. Sau, H.O. Alsaab, K. Bhise, R. Alzhrani, G. Nabil, A.K. Iyer, Multifunctional nanoparticles for cancer immunotherapy: a goundbreaking approach for reprogramming malfunctioned tumor environment. J. Control. Release 274, 24–34 (2018). https://doi.org/10.1016/j.jconrel.2018.01.028
  18. E.A. Scott, N.B. Karabin, P. Augsornworawat, Overcoming immune dysregulation with immunoengineered nanobiomaterials. Annu. Rev. Biomed. Eng. 19, 57–84 (2017). https://doi.org/10.1146/annurev-bioeng-071516-044603
  19. P.L. Mage, A.T. Csordas, T. Brown, D. Klinger, M. Eisenstein, S. Mitragotri, C. Hawker, H.T. Soh, Shape-based separation of synthetic microparticles. Nat. Mater. 18, 82–89 (2019). https://doi.org/10.1038/s41563-018-0244-9
  20. X. Hu, J. Hu, J. Tian, Z. Ge, G. Zhang, K. Luo, S. Liu, Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery. J. Am. Chem. Soc. 135, 17617–17629 (2013). https://doi.org/10.1021/ja409686x
  21. T.J. Merkel, S.W. Jones, K.P. Herlihy, F.R. Kersey, A.R. Shields et al., Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. USA 108, 586–591 (2011). https://doi.org/10.1073/pnas.1010013108
  22. K.C. Meyer, E.N. Coker, D.S. Bolintineanu, B. Kaehr, Mechanically encoded cellular shapes for synthesis of anisotropic mesoporous particles. J. Am. Chem. Soc. 136, 13138–13141 (2014). https://doi.org/10.1021/ja506718z
  23. V. Kozlovskaya, J.F. Alexander, Y. Wang, T. Kuncewicz, X. Liu, B. Godin, E. Kharlampieva, Internalization of red blood cell-mimicking hydrogel capsules with pH-triggered shape reponses. ACS Nano 8, 5725–5737 (2014). https://doi.org/10.1021/nn500512x
  24. C. Xu, S. Hu, X. Chen, Artificial cells: from basic science to applications. Mater. Today 19, 516–532 (2016). https://doi.org/10.1016/j.mattod.2016.02.020
  25. C.H. Park, N.-O. Chung, J. Lee, Monodisperse red blood cell-like particles via consolidation of charged droplets. J. Colloid Interface Sci. 361, 423–428 (2011). https://doi.org/10.1016/j.jcis.2011.06.003
  26. U. Farook, E. Stride, M.J. Edirisinghe, Preparation of suspensions of phospholipid-coated microbubbles by coaxial electrohydrodynamic atomization. J. R. Soc. Interface 6, 271–277 (2009). https://doi.org/10.1098/rsif.2008.0225
  27. S.C. Balmert, S.R. Little, Biomimetic delivery with micro- and nanoparticles. Adv. Mater. 24, 3757–3778 (2012). https://doi.org/10.1002/adma.201200224
  28. R.W. Jenkins, D.A. Barbie, K.T. Flaherty, Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9–16 (2018). https://doi.org/10.1038/bjc.2017.434
  29. P. Schmid, S. Adams, H.S. Rugo, A. Schneeweiss, C.H. Barrios et al., Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018). https://doi.org/10.1056/NEJMoa1809615
  30. L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş et al., Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018). https://doi.org/10.1056/NEJMoa1810865
  31. L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, G. Kroemer, Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015). https://doi.org/10.1016/j.ccell.2015.10.012
  32. G. Kroemer, L. Galluzzi, O. Kepp, L. Zitvogel, Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013). https://doi.org/10.1146/annurev-immunol-032712-100008
  33. L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, G. Kroemer, Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2016). https://doi.org/10.1038/nri.2016.107
  34. D.V. Krysko, A.D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, P. Vandenabeele, Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860–875 (2012). https://doi.org/10.1038/nrc3380
  35. X. Duan, C. Chan, W. Han, N. Guo, R.R. Weichselbaum, W. Lin, Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat. Commun. 10, 1899 (2019). https://doi.org/10.1038/s41467-019-09221-x
  36. S. Goldman, Generalizations of the Young-Laplace equation for the pressure of a mechanically stable gas bubble in a soft elastic material. J. Chem. Phys. 131, 184502 (2009). https://doi.org/10.1063/1.3259973
  37. F.J. Higuera, Stationary viscosity-dominated electrified capillary jets. J. Fluid Mech. 558, 143–152 (2006). https://doi.org/10.1017/S0022112006000024
  38. U. Farook, E. Stride, M.J. Edirisinghe, R. Moaleji, Microbubbling by co-axial electrohydrodynamic atomization. Med. Biol. Eng. Comput. 45, 781–789 (2007). https://doi.org/10.1007/s11517-007-0210-1
  39. V.S. Dave, R.M. Fahmy, S.W. Hoag, Investigation of the physical–mechanical properties of Eudragit® RS PO/RL PO and their mixtures with common pharmaceutical excipients. Drug Dev. Ind. Pharm. 39, 1113–1125 (2013). https://doi.org/10.3109/03639045.2012.714786
  40. P. Decuzzi, R. Pasqualini, W. Arap, M. Ferrari, Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26, 235–243 (2008). https://doi.org/10.1007/s11095-008-9697-x
  41. S. Behzadi, V. Serpooshan, W. Tao, M.A. Hamaly, M.Y. Alkawareek et al., Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46, 4218–4244 (2017). https://doi.org/10.1039/C6CS00636A
  42. H. Herd, N. Daum, A.T. Jones, H. Huwer, H. Ghandehari, C.-M. Lehr, Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano 7, 1961–1973 (2013). https://doi.org/10.1021/nn304439f
  43. L.W. Zhang, N.A. Monteiro-Riviere, Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol. Sci. 110, 138–155 (2009). https://doi.org/10.1093/toxsci/kfp087
  44. R. Toy, P.M. Peiris, K.B. Ghaghada, E. Karathanasis, Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine 9, 121–134 (2014). https://doi.org/10.2217/nnm.13.191
  45. J.A. Roman, I. Reucroft, R.A. Martin, A. Hurtado, H.-Q. Mao, Local release of paclitaxel from aligned, electrospun microfibers promotes axonal extension. Adv. Healthc. Mater. 5, 2628–2635 (2016). https://doi.org/10.1002/adhm.201600415
  46. J. Han, L.A. Goldstein, W. Hou, C.J. Froelich, S.C. Watkins, H. Rabinowich, Deregulation of mitochondrial membrane potential by mitochondrial insertion of granzyme B and direct Hax-1 cleavage. J. Biol. Chem. 285, 22461–22472 (2010). https://doi.org/10.1074/jbc.M109.086587
  47. J. Du, Y. Wang, R. Hunter, Y. Wei, R. Blumenthal et al., Dynamic regulation of mitochondrial function by glucocorticoids. Proc. Natl. Acad. Sci. USA 106, 3543–3548 (2009). https://doi.org/10.1073/pnas.0812671106
  48. C. Garrido, L. Galluzzi, M. Brunet, P.E. Puig, C. Didelot, G. Kroemer, Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 13, 1423–1433 (2006). https://doi.org/10.1038/sj.cdd.4401950
  49. S. Fulda, K.M. Debatin, Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798–4811 (2006). https://doi.org/10.1038/sj.onc.1209608
  50. E.G.E. de Vries, J.A. Gietema, S. de Jong, Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin. Cancer Res. 12, 2390–2393 (2006). https://doi.org/10.1158/1078-0432.CCR-06-0352
  51. M. Obeid, A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh et al., Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2006). https://doi.org/10.1038/nm1523
  52. W. Ou, L. Jiang, R.K. Thapa, Z.C. Soe, K. Poudel et al., Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy. Theranostics 8, 4574–4590 (2018). https://doi.org/10.7150/thno.26758
  53. P. Kadiyala, D. Li, F.M. Nuñez, D. Altshuler, R. Doherty et al., High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13, 1365–1384 (2019). https://doi.org/10.1021/acsnano.8b06842
  54. J. Lu, X. Liu, Y.-P. Liao, F. Salazar, B. Sun et al., Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat. Commun. 8, 1811 (2017). https://doi.org/10.1038/s41467-017-01651-9
  55. J.A. Villadangos, P. Schnorrer, Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 7, 543–555 (2007). https://doi.org/10.1038/nri2103
Read More
Author biographies are not available.
Download this PDF file
PDF SUPPLEMENTARY MATERIAL
Statistic
Read Counter : 4396 Download : 3322